Chun-Hao Huang, PhD

Dr. Chun-Hao Huang is Co-Founder and CEO of Algen. Dr. Huang is a genetic engineer, drug developer and AI entrepreneur. He received his postdoctoral training at UC Berkeley under the mentorship of Nobel Laureate Professor Jennifer Doudna, and his PhD at Memorial Sloan-Kettering Cancer Center/Weill Cornell Medicine under HHMI Professors Scott Lowe and Charles Sherr. Dr. Huang pioneered genetically engineered models using advanced CRISPR and RNAi, which led to the discovery of new therapeutic strategies for treating cancer and inflammatory diseases. He also invented methods to identify disease biomarkers that predict drug responses and applied machine learning to the study of genes. Dr. Huang is the recipient of the UN’s Sustainable Development Goals Talent award of the 1st UNLEASH Global Innovation Lab, a Fellow of the 64th Lindau Nobel Laureate Meeting, and an AACR Basic Cancer Research Fellow. He has authored over 10 patents filed or issued, 40 scientific papers, and 3,000 citations across fields of biotechnology, AI, medicine in top-tier journals including Cell, Science, Nature Biotechnology, and Proceedings of the National Academy of Sciences (PNAS).